At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 114 enrolled
Drug / intervention
Anastrozoledrug
Likely dose
Anastrozole 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer
In Brief
A Phase 4 clinical trial evaluating Anastrozole for Early Breast Cancer. Completed, enrolled 114 participants across 5 sites.
Detailed Summary
The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEarly Breast Cancer
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartJun 2006
Primary CompletionJan 2009
TodayJul 2026
First PostedMay 9, 2006
Enrollment StartJun 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.1 years ago
Interventions
Anastrozoledrug
1mg/Day oral